My PSA chart post primary treatments
I had my primary treatment for prostrate cancer in HUKM
(Hospital University Kebangsaan Malaysia) in January 2010. I had a dual
modality of external beam radiation and hormone treatments. My PSA at that time
was 27 ng /ml with a gleason score of 3+4. I had 32 sessions of radiation and
36 months of Zoladex, injected in my stomach every quarter.
My last Zoladex injection was administered in February 2013
with my PSA suppressed to 0.02 ng/ml throughout my treatment. My Nadir point is
0.02 ng/ml.
By May 2013 my PSA had started to rise slowly and steadily to
0.03 ng/ml, 0.09 ng/ml, and 0.12 ng/ml at every quarter, reaching 0.18 ng/ml in
August 2014. It recorded a steady rise of 0.01 ng/ml per month over 18 months.
The graph in blue (Series 1) above shows the reading values
and the graph in red ( Series 2) shows the amount of increase over 18 months.
Yes we see two doubling rise times, 4 consecutive rises, but with a fairly
slower velocity.
I was advised to be on active surveillance until my PSA
reaches Nadir point plus 2.0 ng/ml which is recognized as prostrate cancer
biochemical failure for radiotherapy/ hormone treatments. It would also be
difficult to scan for any cancer cells at this point of time.
I have since
requested my case to be referred to the IKN (Institute Kanser Negara) in
Putrajaya for further surveillance/treatments.
At IKN I was also placed in active surveillance. My next
appointment is scheduled on 02 December 2014.
I am still reading into the value and benefits of early
aggressive salvage treatments vis-a-vis aggressive active surveillance for
disease progression until we have a confirmation of a local or distant failure.
Tough choice.
Allen Lai
No comments:
Post a Comment